Digital Pathology Industry Overview
The global digital pathology market size was valued at USD 1.03 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 8.0% from 2024 to 2030. This is attributed to rising prevalence of cancer, increasing focus on improving the efficiency of workflow, and growing demand for faster diagnostic tools. Moreover, rising investments in healthcare aided by major key players operating in the market focusing on new launches, increasing adoption of telepathology, and an increasing focus on drug discovery and precision medicine is propelling the market growth.
Gather more insights about the market drivers, restrains and growth of the Digital Pathology Market
Rising adoption of healthcare IT solutions is fueling the demand for digital pathology solutions. Organizations are increasingly implementing them to cut costs, streamline processes, overcome resource bottlenecks, and facilitate efficient content sharing. A growing necessity for collaborations and the expanding use of digital documentation across various scientific disciplines also drives the demand. In addition, factors such as heightened adoption to enhance laboratory efficiency, a surge in teleconsultations, and increased applications in companion diagnostics and drug discovery are expected to contribute to the market's growth.
During the COVID-19 pandemic, government organizations in various countries, research institutes, and many pharmaceutical biotech firms focused on effective rapid technologies for accurate COVID-19 diagnosis and development of vaccines/new therapeutics to combat the pandemic. COVID-19 tested diagnostic services at a time when many histopathology departments were already understaffed and overburdened. Furthermore, it had a significant impact on routine pathology services. During the pandemic, digital pathology was critical in protecting clinical services and pathology-based research.
Browse through Grand View Research's Healthcare IT Industry Research Reports.
- The global precision medicine market size was estimated at USD 87.50 billion in 2023 and is projected to grow at a CAGR of 16.3% from 2024 to 2030.
- The global oncology clinical trials market size was estimated at USD 12.92 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 5.2% from 2023 to 2030.
Digital Pathology Market Segmentation
Grand View Research has segmented the global digital pathology market based on product, type, application, end-use, and region:
Digital Pathology Product Outlook (Revenue, USD Billion, 2018 - 2030)
- Software
- Device
- Scanners
- Slide Management System
- Storage System
Digital Pathology Type Outlook (Revenue, USD Billion, 2018 - 2030)
- Human Pathology
- Veterinary Pathology
Digital Pathology Application Outlook (Revenue, USD Billion, 2018 - 2030)
- Drug Discovery Development
- Academic Research
- Disease Diagnosis
- Cancer Cell Detection
- Others
Digital Pathology End-use Outlook (Revenue, USD Billion, 2018 - 2030)
- Hospitals
- Biotech Pharma Companies
- Diagnostic Labs
- Academic Research Institutes
Digital Pathology Regional Outlook (Revenue, USD Billion, 2018 - 2030)
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- ROE
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- RoAPAC
- Latin America
- Brazil
- Mexico
- Argentina
- RoLATAM
- Middle East Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Key Companies profiled:
- Leica Biosystems Nussloch GmbH (Danaher)
- Hamamatsu Photonics, Inc.
- Koninklijke Philips N.V.
- Olympus Corporation
- F. Hoffmann-La Roche Ltd.
- Mikroscan Technologies, Inc.
- Inspirata, Inc.
- Epredia (3DHISTECH Ltd.)
- Visiopharm A/S
- Huron Technologies International Inc.
- ContextVision AB
- CellaVision
- HANGZHOU ZHIWEI INFORMATION TECHNOLOGY CO. LTD. (MORPHOGO)
- West Medica Produktions- und Handels- GmbH (West Medica)
- aetherAI
- IBEX (IBEX MEDICAL ANALYTICS)
- SigTuple Technologies Private Limited
- Morphle Labs, Inc
- Bionovation Biotech, Inc.
Key Digital Pathology Company Insights
In July 2022, CellaVision introduced the DIFF-Line, a workflow system designed specifically for low-volume hematology laboratories, at the AACC Convention, Chicago, U.S. This solution consists of three instruments, including the CellaVision DC-1, RAL SmearBox, and RAL StainBox, which are used for smearing, staining, and analyzing peripheral blood smears. This technology was made available in the European markets in July 2022, with plans to expand to other regions in the same year.
"DIFF-Line by CellaVision is a comprehensive solution for small labs that want to improve diagnostic certainty. With the acquisition of RAL Diagnostics, CellaVision can now offer a complete workflow for smearing, staining, and analyzing peripheral blood smears in hematology labs that handle a smaller amount of daily blood samples.”
- Simon Ostergaard, CellaVision CEO,
In February 2020, Scopio Labs, a company dedicated to advancing digital microscopy, announced the launch of ScopioVet Digital Cytology System in the United States and Canada. It is the first true end-to-end solution for veterinary digital cytology, consisting of Scopio's proprietary microscopy imaging system, an intuitive pathology consultation service and powerful AI tools that automate routine diagnostic tests.
"The diagnostic practice of cytology and hematology is designed to be a less invasive and significantly faster option than histology. However, when veterinarians and pet parents wait several days for results to come back, as is the case in most veterinary practices worldwide, the value of cytology is reduced. ScopioVet corrects this dynamic, by providing results in less than an hour, unlocking the true value of cytology and improving the standard of care so veterinarians can deliver exceptional service with improved outcomes."
- Asher Fink, Veterinary Business Head and VP of Business Development for Scopio Labs.
Order a free sample PDF of the Digital Pathology Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
